TODD ROSENGART to Genetic Therapy
This is a "connection" page, showing publications TODD ROSENGART has written about Genetic Therapy.
Connection Strength
3.201
-
Cardiac stem cell trials and the new world of cellular reprogramming: Time to move on. J Thorac Cardiovasc Surg. 2018 04; 155(4):1642-1646.
Score: 0.378
-
Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease. Hum Gene Ther. 2013 Feb; 24(2):203-8.
Score: 0.267
-
Cardiac biointerventions: whatever happened to stem cell and gene therapy? Innovations (Phila). 2012 May-Jun; 7(3):173-9.
Score: 0.256
-
Double-blinded, placebo-controlled, randomized gene therapy using surgery for vector delivery. Hum Gene Ther. 2012 May; 23(5):438-41.
Score: 0.255
-
Gene therapy for heart failure. Semin Thorac Cardiovasc Surg. 2005; 17(4):343-7.
Score: 0.154
-
Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial. Circ Cardiovasc Interv. 2024 05; 17(5):e014054.
Score: 0.147
-
Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state. J Thorac Cardiovasc Surg. 2004 Feb; 127(2):535-40.
Score: 0.144
-
Therapeutic angiogenesis: a biologic bypass. Cardiology. 2004; 101(1-3):131-43.
Score: 0.143
-
Introduction: the era of cardiac biointerventions. Semin Thorac Cardiovasc Surg. 2003 Jul; 15(3):217-21.
Score: 0.139
-
Gene therapy with adenovirus-mediated myocardial transfer of vascular endothelial growth factor 121 improves cardiac performance in a pacing model of congestive heart failure. J Thorac Cardiovasc Surg. 2002 Jun; 123(6):1101-13.
Score: 0.129
-
Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations. Am Heart J. 2021 11; 241:38-49.
Score: 0.121
-
Percutaneous endocardial transfer and expression of genes to the myocardium utilizing fluoroscopic guidance. Catheter Cardiovasc Interv. 2001 Feb; 52(2):260-6.
Score: 0.117
-
Gene therapy for coronary artery disease. Adv Card Surg. 2001; 13:107-20.
Score: 0.117
-
Cardiac angiogenesis and gene therapy: a strategy for myocardial revascularization. Curr Opin Cardiol. 1999 Nov; 14(6):515-22.
Score: 0.107
-
Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Surg. 1999 Oct; 230(4):466-70; discussion 470-2.
Score: 0.107
-
Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation. 1999 Aug 03; 100(5):468-74.
Score: 0.106
-
Exogenous control of cardiac gene therapy: evidence of regulated myocardial transgene expression after adenovirus and adeno-associated virus transfer of expression cassettes containing corticosteroid response element promoters. J Thorac Cardiovasc Surg. 1999 Jul; 118(1):26-4, discussion 34-5.
Score: 0.105
-
Therapeutic angiogenesis: protein and gene therapy delivery strategies. J Cardiovasc Risk. 1999 Feb; 6(1):29-40.
Score: 0.102
-
Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease. Hum Gene Ther. 2013 Nov; 24(11):948-63.
Score: 0.071
-
An Egr-1 master switch for arteriogenesis: studies in Egr-1 homozygous negative and wild-type animals. J Thorac Cardiovasc Surg. 2006 Jan; 131(1):138-45.
Score: 0.041
-
Alteration of splicing signals in a genomic/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms enhances safety of angiogenic gene therapy. Mol Ther. 2005 Oct; 12(4):716-24.
Score: 0.040
-
Adenovirus-mediated transfer of a minigene expressing multiple isoforms of VEGF is more effective at inducing angiogenesis than comparable vectors expressing individual VEGF cDNAs. Mol Ther. 2004 Jan; 9(1):67-75.
Score: 0.036
-
Systemic interleukin-6 responses following administration of adenovirus gene transfer vectors to humans by different routes. Mol Ther. 2002 Aug; 6(2):287-97.
Score: 0.032
-
Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation. 2000 Sep 12; 102(11):E73-86.
Score: 0.029
-
Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg. 2000 Jan; 69(1):14-23; discussion 23-4.
Score: 0.027
-
Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats. Hum Gene Ther Clin Dev. 2013 Mar; 24(1):38-46.
Score: 0.017
-
Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum Gene Ther. 2002 Jan 01; 13(1):15-63.
Score: 0.008
-
Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther. 2002 Jan 01; 13(1):65-100.
Score: 0.008